Momenta to evaluate safety of heart attack therapy
The study will evaluate M118, a next-generation anticoagulant designed specifically for use in treating patients diagnosed with acute coronary syndromes (ACS). M118 will also be tested for its
WellSpan Health and Johns Hopkins Medicine have renewed their oncology collaboration, aiming to widen patient access to advanced care, clinical expertise, and research initiatives throughout central Pennsylvania, US.